Drugs / JNJ-67571244
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03915379 | Mar 2019 → Mar 2022 | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-67571244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03915379 ↗ |